Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.

来源：https://techcrunch.com/2026/08/29/were-not-doing-30-bets-a-year-vijay-pande-on-betting-small-after-running-4-billion-at-a16z/